Main Category: Cancer / Oncology
Also Included In: Dermatology; Immune System / Vaccines
Article Date: 21 Oct 2008 - 3:00 PDT
Adoptive Cell Transfer Therapy!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
DR. Steven A. Rosenberg at The National Cancer Institute
Melanoma patients infused with a special type of tumor-fighting T cell are more likely to survive without relapse, suggests a new study by researchers in France. Their report was published online on October 20 in the Journal of Experimental Medicine.
One treatment option for patients with late-stage melanoma involves removing natural cancer-fighting T cells from the tumor, expanding their numbers in culture dishes, and then re-infusing them into the patient. This strategy - called adoptive immunotherapy - causes tumor regression in about half the patients treated, some of whom survive for decades without relapse.
The French team, lead by Dr. Nathalie Labarriere, studied the infused cells from 30 stage III melanoma patients who had received adoptive immunotherapy between 1994 and 1998. Among the cells taken from a patient who has remained tumor-free for more than a decade, they found naturally-arising T cells that recognized a new protein, which they dubbed "meloe-1." Meloe-1, the group found, is highly expressed in melanoma cells but not in normal skin cells or in other types of cancer.
When they looked at the transferred cells from the other patients, they found meloe-1-specific T cells in 5 of the 9 patients who remained relapse-free, but in none of the 21 patients who relapsed. The association of meloe-1-specific T cells with relapse-free survival suggests that amplifying these T cells in culture may be one way to improve the efficacy of adoptive immunotherapy. The team has also succeeded in finding meloe-1 T cells in patients' circulating blood - a much more accessible source than tumor tissue.
----------------------------
Article adapted by Medical News Today from original press release.
----------------------------
That is a 50%+ complete Response WE are half way there!!!!!!!!!
It can also be done by CTLA-4 Blockage to stimulate the T CELL.
That is what Happen to me. And then we did the IL-2 for the cell to cell
commumination.
WE are getting Closer to the CCCCC UUUUU RRRRR EEEEE!!!!!
Five-year View
"Several advances are being made in the field of immunological and targeted therapies. In our opinion, the agents of most interest in the next 5 years would be the anti-CTLA-4 antibodies and angiogenesis inhibitors combined with cytotoxic therapy. While most of these novel agents may not have significant single-agent activity, combining them with systemic chemotherapy might be the key to clinical success in melanoma. Ultimately, rational combination therapeutics of multimodal targeting agents (immunotherapeutics, cytotoxic therapy, angiogenesis inhibitors) will likely lead to substantive clinical benefit in this patient population. Our hope is that this massive clinical research endeavor will soon yield the long sought after improvement in the overall survival of patients with advanced melanoma."
Dr.Svetomir N Markovic
Rajini Katipamula; Svetomir N Markovic
Expert Rev Anticancer Ther. 2008;8(4):553-560.
Posted 07/09/2008
Svetomir N. Markovic, M.D.
Location: Minnesota
Education
Fellowship – Department of Internal Medicine; Division of Hematology, Department of Oncology
Mayo Graduate School of Medicine
Residency – Internal Medicine
Mayo Graduate School of Medicine
M.D.
Medical College of Pennsylvania
Fellowship – Part-time Post-doctoral; Microbiology/Immunology, Pharmacology
Medical College of Pennsylvania
Ph.D. – Department of Microbiology/Immunology
Medical College of Pennsylvania
Summary
Translational immunotherapeutics of cancer focused on malignant melanoma and non-Hodgkin's lymphoma. This work includes development and clinical testing of: cancer vaccines; immune boosting agents; novel agents that reconstitute immunity in patients with cancer; and combination therapy directed at enhancing anti-tumor immune responses.
No comments:
Post a Comment